VYNE Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
YARW$15.48-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements Of Cash Flows
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(U.S. dollars in thousands)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash Flows From Operating Activities: | ||
| Net loss | $(6,249) | $(5,622) |
| Adjustments required to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 985 | 856 |
| Amortization of premium or discount on marketable securities | (777) | — |
| Unrealized losses on cash equivalents | (1) | — |
| Changes in operating assets and liabilities: | ||
| Trade receivables, prepaid expenses and other assets and operating lease right-of-use assets | (1,294) | (200) |
| Trade payables, accrued expenses, employee related obligations and other long-term liabilities | (612) | (512) |
| Operating lease liabilities | (34) | — |
| Net cash used in operating activities | (7,982) | (5,478) |
| Cash Flows From Investing Activities: | ||
| Proceeds from the sale of the MST Franchise | — | 5,000 |
| Proceeds from sale and maturity of marketable securities | 11,600 | — |
| Purchases of marketable securities | (15,169) | — |
| Net cash (used in) provided by investing activities | (3,569) | 5,000 |
| Cash Flows From Financing Activities: | ||
| Proceeds related to issuance of common stock through at-the-market offerings, net of issuance costs | — | 156 |
| Redemption of convertible preferred stock | — | (360) |
| Withholdings from exercise of options and issuance of shares for stock-based compensation arrangements, net | (4) | (13) |
| Net cash used in financing activities | (4) | (217) |
| Decrease in cash, cash equivalents and restricted cash | (11,555) | (695) |
| Cash, cash equivalents and restricted cash at beginning of the period | 30,674 | 30,975 |
| Cash, cash equivalents and restricted cash at end of the period | $19,119 | $30,280 |
| Cash and cash equivalents | 19,065 | 30,213 |
| Restricted cash | 54 | 67 |
| Total cash, cash equivalents and restricted cash | $19,119 | $30,280 |
| Supplementary information on investing and financing activities not involving cash flows: | ||
| Accretion of preferred stock | $— | $149 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.